## **Resource Summary Report**

Generated by <u>NIF</u> on May 5, 2025

# Loma Linda University Cancer Center Biospecimen Laboratory

RRID:SCR\_004767 Type: Tool

**Proper Citation** 

Loma Linda University Cancer Center Biospecimen Laboratory (RRID:SCR\_004767)

#### **Resource Information**

URL: http://lomalindahealth.org/medical-center/our-services/cancer-center/cancer-resource-center/biospecimen-laboratory.html

**Proper Citation:** Loma Linda University Cancer Center Biospecimen Laboratory (RRID:SCR\_004767)

**Description:** The Loma Linda University Cancer Center Biospecimen Laboratory provides specimens for researchers as they search for the causes of cancer, and look for new means of prevention and treatment. The specimens include tissues, blood products (blood cell, plasma and serum) and bone marrow cells. Researchers interested in gaining access to the Biospecimen Laboratory''s samples should email Dr. Saied Mirshahidi, requesting access. The number and types of samples we have available for research can be viewed, http://www.llu.edu/catissuesummary/. Use the Biospecimen Laboratory Tissue Request Form to request specimens for research studies.

Abbreviations: LLU Cancer Center Biospecimen Laboratory

Resource Type: biomaterial supply resource, tissue bank, material resource

Related Condition: Cancer

Funding:

Resource Name: Loma Linda University Cancer Center Biospecimen Laboratory

Resource ID: SCR\_004767

Alternate IDs: nlx\_76868

Record Creation Time: 20220129T080226+0000

Record Last Update: 20250505T053604+0000

#### **Ratings and Alerts**

No rating or validation information has been found for Loma Linda University Cancer Center Biospecimen Laboratory.

No alerts have been found for Loma Linda University Cancer Center Biospecimen Laboratory.

### Data and Source Information

Source: <u>SciCrunch Registry</u>

#### **Usage and Citation Metrics**

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>NIF</u>.

Shouse G, et al. (2016) Novel B55?-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget, 7(38), 61081.